Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Brachytherapy of the prostatic cancer by interstitial permanent implantation of iodine-125].
Chauveinc L, Salem N, Pommier P, Peiffert D, Guerif S, Hannoun-Levy JM, Labib A, Delannes M, Hennequin C, Moncho V, Cosset JM, Mallet F, Flam T; Groupe des utilisateurs de la curiethérapie à implantation permanente pour les cancers de la prostate. Chauveinc L, et al. Among authors: guerif s. Cancer Radiother. 2002 Apr;6(2):112-5. doi: 10.1016/s1278-3218(02)00156-7. Cancer Radiother. 2002. PMID: 12035482 French. No abstract available.
[Prostate cancer brachytherapy].
Pommier P, Guérif S, Peiffert D, Créhange G, Hannoun-Lévi JM, de Crevoisier R. Pommier P, et al. Among authors: guerif s. Cancer Radiother. 2016 Sep;20 Suppl:S210-5. doi: 10.1016/j.canrad.2016.07.038. Epub 2016 Aug 11. Cancer Radiother. 2016. PMID: 27523412 French.
[Clinical and dosimetric analysis of 469 prostate cancer patients treated in France in 2005 by permanent implant brachytherapy using the Iodin 125 seeds IsoSeed Bebig: report to the French Economic committee of health products (CEPS)].
Cosset JM, Gomme S, Peiffert D, Guerif S, Labib A, Hannoun-Lévi JM, Martin P, Quétin P, Nguyen TD, Flam T, Thiounn N, Henni M, Rosenwald JC, Housset M, Pontvert D, Asselain B, Chauveinc L. Cosset JM, et al. Among authors: guerif s. Cancer Radiother. 2007 Jun;11(4):206-13. doi: 10.1016/j.canrad.2007.05.003. Epub 2007 Jun 28. Cancer Radiother. 2007. PMID: 17604675 French.
[Postoperative radiotherapy of prostate cancer].
Guérif S, Latorzeff I, Lagrange JL, Hennequin C, Supiot S, Garcia A, François P, Soulié M, Richaud P, Salomon L. Guérif S, et al. Cancer Radiother. 2014 Oct;18(5-6):517-23. doi: 10.1016/j.canrad.2014.07.149. Epub 2014 Sep 5. Cancer Radiother. 2014. PMID: 25195116 Review. French.
[Hypofractionated radiotherapy in prostate cancer].
Supiot S, Créhange G, Latorzeff I, Pommier P, Paumier A, Rio E, Delaroche G, Guérif S, Catton C, Martin J, Lisbona A. Supiot S, et al. Among authors: guerif s. Cancer Radiother. 2013 Oct;17(5-6):349-54. doi: 10.1016/j.canrad.2013.05.005. Epub 2013 Aug 20. Cancer Radiother. 2013. PMID: 23973460 Review. French.
[Target-volume and critical-organ delineation for conformal radiotherapy of prostate cancer: experience of French dose-escalation trials].
Beckendorf V, Bachaud JM, Bey P, Bourdin S, Carrie C, Chapet O, Cowen D, Guérif S, Hay HM, Lagrange JL, Maingon P, Le Prisé E, Pommier P, Simon JM. Beckendorf V, et al. Among authors: guerif s. Cancer Radiother. 2002 Nov;6 Suppl 1:78s-92s. doi: 10.1016/s1278-3218(02)00217-2. Cancer Radiother. 2002. PMID: 12587386 Review. French.
[Propositions for the selection and the delineation of peritumoral microscopic disease volumes in oral cavity and oropharyngeal cancers (lymph nodes excluded)].
Lapeyre M, Henrot P, Alfonsi M, Bardet E, Bensadoun RJ, Dolivet G, Favrel V, Gallocher O, Giraud P, Graff P, Guerif S, Lagarde P, Lartigau E, Marchesi V, Pommier P, Rives M, Tortochaux J, Toussaint B, Verrelle P, Bourhis J, Calais G; Groupe Oncologie Radiothérapie Tête et Cou. Lapeyre M, et al. Among authors: guerif s. Cancer Radiother. 2005 Jun;9(4):261-70. doi: 10.1016/j.canrad.2005.03.005. Epub 2005 Apr 25. Cancer Radiother. 2005. PMID: 16081023 Review. French.
Patterns of practice of androgen deprivation therapy combined to radiotherapy in favorable and unfavorable intermediate risk prostate cancer. Results of The PROACT Survey from the French GETUG Radiation Oncology group.
Belkacemi Y, Latorzeff I, Hasbini A, Coraggio G, Pasquier D, Toledano A, Hennequin C, Bossi A, Chapet O, Crehange G, Guerif S, Duberge T, Allouache N, Clavere P, Gross E, Supiot S, Azria D, Bolla M, Sargos P. Belkacemi Y, et al. Among authors: guerif s. Cancer Radiother. 2020 Dec;24(8):892-897. doi: 10.1016/j.canrad.2020.03.014. Epub 2020 Nov 2. Cancer Radiother. 2020. PMID: 33144063 Review.
47 results